- Home
- GHY vs FLGT Comparison
GHY vs FLGT Comparison
Compare GHY & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHY
- FLGT
- Stock Information
- Founded
- GHY 2012
- FLGT 2011
- Country
- GHY United States
- FLGT United States
- Employees
- GHY N/A
- FLGT N/A
- Industry
- GHY Trusts Except Educational Religious and Charitable
- FLGT Medical Specialities
- Sector
- GHY Finance
- FLGT Health Care
- Exchange
- GHY Nasdaq
- FLGT Nasdaq
- Market Cap
- GHY 528.3M
- FLGT 508.7M
- IPO Year
- GHY N/A
- FLGT 2016
- Fundamental
- Price
- GHY $13.25
- FLGT $16.46
- Analyst Decision
- GHY
- FLGT Hold
- Analyst Count
- GHY 0
- FLGT 1
- Target Price
- GHY N/A
- FLGT $22.00
- AVG Volume (30 Days)
- GHY 184.8K
- FLGT 225.7K
- Earning Date
- GHY 01-01-0001
- FLGT 02-28-2025
- Dividend Yield
- GHY 10.58%
- FLGT N/A
- EPS Growth
- GHY N/A
- FLGT N/A
- EPS
- GHY N/A
- FLGT N/A
- Revenue
- GHY N/A
- FLGT $277,761,000.00
- Revenue This Year
- GHY N/A
- FLGT N/A
- Revenue Next Year
- GHY N/A
- FLGT $16.00
- P/E Ratio
- GHY N/A
- FLGT N/A
- Revenue Growth
- GHY N/A
- FLGT N/A
- 52 Week Low
- GHY $10.24
- FLGT $15.99
- 52 Week High
- GHY $11.92
- FLGT $25.50
- Technical
- Relative Strength Index (RSI)
- GHY 54.89
- FLGT 42.71
- Support Level
- GHY $13.06
- FLGT $16.47
- Resistance Level
- GHY $13.54
- FLGT $17.39
- Average True Range (ATR)
- GHY 0.17
- FLGT 0.54
- MACD
- GHY -0.02
- FLGT 0.10
- Stochastic Oscillator
- GHY 53.23
- FLGT 33.57
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.